Three generic drugmakers — Teva Pharmaceuticals, Mylan and Ranbaxy — will pay $65.9 million to settle claims that they engaged in a scheme promoting anticompetitive behavior, according to Reuters.
The lawsuit claims that the three drugmakers participated in pay-for-delay deals to prevent the release of a generic, cheaper version of the wakefulness drug Provigil.
The settlement resolves a class-action lawsuit brought by health plans and other indirect purchasers of Provigil.
Read the full report here.